stockrow
Friday 6 November 2026
Export BLLN’s income statement to Excel — free account
BillionToOne, Inc.
BLLN Healthcare Diagnostics & Research
BillionToOne, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $305.1 million, up 100.0% from fiscal 2024.
- Revenue
- +47.2%
- EPS
- +164.3%
- Free cash flow
- +9.25%
- Total debt
- +60.6%
Quarter to September 2026, against a year earlier
111.96
1.93
−1.69%
Follow BLLN
Alert me
BillionToOne, Inc. (BLLN) EBITDA
BillionToOne, Inc.'s EBITDA for fiscal 2025 was $27.9M, compared with −$35.1M in fiscal 2024. Over the twelve months to 30 June 2026 it was $55.6M. BillionToOne, Inc. ranks 20th of 49 Diagnostics & Research companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $27.9M | — |
| FY2024 | −$35.1M | — |
| FY2023 | −$62.5M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $8.9M | (57.27%) |
| Mar 2026 | $20.8M | 56.67% |
| Dec 2025 | $13.3M | 5.62% |
| Sep 2025 | $12.6M | 826.73% |
| 3 more quarters | Free account |
EBITDA against peers
| Company | EBITDA |
|---|---|
| QGEN QIAGEN N.V. compare | $651.0M |
| SHC Sotera Health Company compare | $537.0M |
| RDNT RadNet, Inc. compare | $307.7M |
| CDNA CareDx, Inc. compare | $141.4M |
| VCYT Veracyte, Inc. compare | $123.9M |
| BLLN BillionToOne, Inc. | $55.6M |
| NEO NeoGenomics, Inc. compare | $17.5M |
| ADPT Adaptive Biotechnologies Corporation compare | −$22.4M |
| GRAL GRAIL, Inc. compare | −$400.6M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on BLLN
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Shares outstanding
- Book value per share
- The full statement